CORRECTING and REPLACING: DEINOVE: DNV3681's Exceptional Activity Against Bioterrorist Threats Presented at ASM Microbe 2019
25 Juin 2019 - 4:05PM
Business Wire
Regulatory News:
This replaces the announcement made at 6:00pm
CEST on June 24th, 2019 due to the following correction, in the
second paragraph: 0.015 µg/ml instead of 0.015 g/ml
DEINOVE:
DNV3681's Exceptional Activity Against Bioterrorist Threats
Presented at ASM Microbe 2019
- Major Steven Zumbrun (USAMRIID1, U.S. Department of
Defense) presented data on the in vitro assessment of DNV3681
against pathogens classified as "high priority" bioterrorist
threats, last week in San Francisco.
- DNV3681 has demonstrated exceptional activity against Bacillus
anthracis, superior to that of Ciprofloxacin, one of the reference
treatments.
- On the basis of these data, USAMRIID intends to conduct the in
vivo assessment of DNV3681 against Bacillus anthracis, the
bacterium that causes anthrax.
DEINOVE (Paris:ALDEI), a French biotech company that uses a
disruptive approach to develop innovative antibiotics and bio-based
active ingredients for cosmetics and nutrition, disclosed the
details of the paper presented last Friday at the ASM Microbe 2019
congress by Major Steven Zumbrun, PhD in Microbiology at the U.S.
Army Medical Research Institute of Infectious Diseases
(USAMRIID).
Major Steven Zumbrun presented the results of the in vitro
evaluation of DNV3681 against Bacillus anthracis and Francisella
tularensis. He concluded that DNV3681 has "exceptional activity"
against these two bio-threat agents. The USAMRIID team determined
the efficacy of DNV3681 by measuring its MIC90, the minimum
concentration necessary to inhibit the growth of 90% of a panel of
test bacterial isolates. This value is 0.015 µg/ml against Bacillus
anthracis, making it a more effective molecule than
Ciprofloxacin.
Bacillus anthracis and Francisella tularensis are classified as
two of the most dangerous possible biological weapons. The standard
of care against Bacillus anthracis and Francisella tularensis is
currently Ciprofloxacin, a synthetic large spectrum antibiotic from
the fluoroquinolones’ family. Several pathogenic bacterial species
have already developed a resistance against this family of
antibiotics and the long treatment needed for Post-exposure
Prophylaxis of Anthrax very often triggers a major intestinal
microbiota imbalance leading to likely Clostridioides difficile
infections. Therefore, there is an urgency to make efficient and
validated alternatives available. The fact that the DNV3681 is
precisely very active against both Bacillus anthracis and
Clostridioides difficile makes it an ideal candidate to fulfill
that need.
Dr Georges Gaudriault, Scientific Director of Deinove and
co-author of the study, said: "In addition to its superior in
vitro efficacy to current treatments, the results of the clinical
trials that we are currently conducting for the treatment of
Clostridioides difficile infections have shown that DNV3681 also
has the advantage of having a limited impact on the intestinal
microbiota in healthy volunteers, thus limiting the risks of
associated complications. We closely follow the research conducted
by USAMRIID, who is considering, on the basis of the results
presented at ASM Microbe 2019, an in vivo evaluation of our
antibiotic candidate. »
The poster "DNV3681 is a Novel Quinolonyl-Oxazolidinone
Antibacterial with Potent Activity against Biothreat Pathogens" is
available by clicking here.
ABOUT USAMRIID
USAMRIID is celebrating its 50th year of providing leading edge
medical capabilities to deter and defend against current and
emerging biological threat agents. The Institute is the only
laboratory in the Department of Defense equipped to safely study
highly hazardous viruses requiring maximum containment at Biosafety
Level 4. Research conducted at USAMRIID leads to medical
solutions—vaccines, drugs, diagnostics, and information—that
benefit both military personnel and civilians. Established in 1969,
the Institute plays a key role as the lead military medical
research laboratory for the Defense Threat Reduction Agency’s Joint
Science and Technology Office for Chemical and Biological Defense.
USAMRIID is a subordinate laboratory of the U.S. Army Medical
Research and Materiel Command.
For more information, visit www.usamriid.army.mil.
[The information contained in this press release does not
necessarily reflect the position or the policy of the Government
and no official endorsement should be inferred.]
ABOUT DEINOVE
DEINOVE is a French biotechnology company, a leader in
disruptive innovation, which aims to help meet the challenges of
antibiotic resistance and the transition to a sustainable
production model for the cosmetics and nutrition industries.
DEINOVE has developed a unique and comprehensive expertise in
the field of rare bacteria that it can decipher, culture, and
optimize to disclose unsuspected possibilities and induce them to
produce biobased molecules with activities of interest on an
industrial scale. To do so, DEINOVE has been building and
documenting since its creation an unparalleled biodiversity bank
that it exploits thanks to a unique technological platform in
Europe.
DEINOVE is organized around two areas of expertise:
- ANTIBIOTICS, New-generation anti-infective agents:
DEINOVE is preparing to enter a first antibiotic candidate into
Phase II. The Company is also pursuing the systematic exploration
of biodiversity to supply its portfolio with new leads, drawing
notably on partnerships with bioMérieux and Naicons (AGIR program
supported by Bpifrance).
- BIOACTIVES, Active ingredients of natural origin with
cosmetics as the first market and potential in nutrition and
health: DEINOVE already markets a first innovative active
ingredient, a second in partnership with Greentech, while others
are in development with Dow and Oléos (Hallstar Group). It also
runs a program in animal nutrition with Groupe Avril.
Within the Euromedecine science park located in Montpellier,
DEINOVE employs 62 employees, mainly researchers, engineers, and
technicians, and has filed more than 300 patent applications
internationally. The Company has been listed on EURONEXT GROWTH®
since April 2010.
Visitez www.deinove.com
1 The USAMRIID (U.S. Army Medical Research Institute of
Infectious Diseases) is the U.S. Army’s main institution and
facility for defensive research into countermeasures against
biological warfare.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190625005674/en/
Investors Coralie Martin Marketing, Communication et Relations
investisseurs Ph. : +33 (0)4 48 19 01 60
coralie.martin@deinove.com
Media ALIZE RP Aurore Gangloff Ph.: + 33 (0) 6 49 57 82 68
deinove@alizerp.com